Gene Correction Programs

About Peter Biotherapeutics

Peter Biotherapeutics is a private, preclinical-stage biotech founded in 2020, developing next-generation gene-editing therapies. Its flagship platform, RITDM™ 2.0, is a novel gene-editing technology that avoids creating double-strand DNA breaks and uses no bacterial or viral components, potentially offering a superior safety profile and enabling repeat dosing. The company is initially targeting genetic diseases such as metabolic disorders, sickle cell disease, and Duchenne Muscular Dystrophy, as well as oncology, leveraging a leadership team and scientific advisory board with deep expertise in genetics and drug development.

Therapeutic Areas